Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company focused on precision cancer medicines, and its news flow reflects ongoing progress in oncology research, clinical development, and corporate strategy. The company describes itself as dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer, using the genetic principle of synthetic lethality to identify and pursue critical targets in tumors.
News about Tango Therapeutics often highlights updates from its clinical pipeline, including vopimetostat (TNG462), an oral MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, TNG456, a brain-penetrant PRMT5 inhibitor in development for glioblastoma and malignant glioma, and TNG260, a first-in-class CoREST complex inhibitor being evaluated with pembrolizumab in STK11-mutant solid tumors. Press releases have detailed Phase 1/2 clinical data, trial enrollment status, and regulatory designations such as Orphan Drug Designation for TNG456.
The company also issues news on corporate and financial developments, including leadership transitions, board appointments, equity financings, and at-the-market offering agreements documented in SEC filings. Announcements about participation in major healthcare investment conferences and scientific meetings, such as the J.P. Morgan Healthcare Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting, provide additional context on how Tango Therapeutics communicates its strategy and data to investors and the scientific community.
Investors and followers of TNGX can use this news page to review company-issued press releases on clinical results, pipeline milestones, financing transactions, and governance changes, offering a consolidated view of how Tango Therapeutics is advancing its precision oncology programs based on synthetic lethality and targeted cancer biology.
Tango Therapeutics (NASDAQ: TNGX) announced that Malte Peters, M.D., President and CEO, will appear in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The event will be webcast live and a replay will be archived on the company website for 90 days.
Tango Therapeutics (NASDAQ: TNGX) announced a leadership transition effective January 8, 2026: founding CEO Barbara Weber, M.D. will retire as CEO and serve as Executive Chair for 2026 before becoming non-executive chair in 2027. Malte Peters, M.D., a current board member since 2018 with late‑stage development and regulatory experience, is named President and CEO effective immediately. Alexis Borisy will transition to Lead Independent Director. The company reiterated clinical milestones for 2026, including multiple vopimetostat combination trial readouts and monotherapy updates, start of a 2L pancreatic cancer pivotal study, and initial safety/efficacy data for TNG456.
Tango Therapeutics (NASDAQ: TNGX) announced that Sung Lee has been appointed to its Board of Directors effective Jan. 5, 2026. Lee brings over 20 years of finance leadership in biopharma and technology and currently serves as Executive Vice President and Chief Financial Officer at Cytokinetics (role assumed May 2024).
The company highlighted Lee's experience in corporate strategy, investor relations, and finance as supportive for advancing its lead program, vopimetostat, into registrational studies and for growing the organization for late-stage clinical development. Lee's prior roles include CFO at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics, 14 years at Gilead Sciences, and early-career work in tax advisory at PwC. His education includes a bachelor's in economics from UC Irvine and a Master of Business Taxation from USC.
Tango Therapeutics (NASDAQ: TNGX) said CEO Barbara Weber, M.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST / 12:45pm EST.
The presentation will be streamed live via the Investors > Events & Presentations page on the company's website, and a replay will be archived on the website for 90 days after the event.
Tango Therapeutics (NASDAQ: TNGX) announced that Adam Crystal, M.D., Ph.D., President of Research & Development, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 1:30pm ET.
The event will be live webcast via the company's Investors > Events & Presentations page on the day of the presentation, and a replay will be archived on the company's website for 90 days following the presentation.
Tango Therapeutics (NASDAQ: TNGX) announced that CEO Barbara Weber, M.D. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, 4:30–4:55 PM GMT / 11:30–11:55 AM ET. The session will be available live via webcast under the "Events & Presentations" tab on the company's Investors page. A replay will be archived on the company's website for 90 days after the presentation.
Tango Therapeutics (NASDAQ: TNGX) reported Q3 2025 results and operational updates on Nov 4, 2025. Key clinical data include vopimetostat mPFS 7.2 months in 2L MTAP-del pancreatic cancer and a 49% ORR with mPFS 9.1 months in a 13‑histology MTAP-del cohort. Vopimetostat combination studies with Revolution Medicines’ RAS(ON) inhibitors are ongoing with initial data expected in 2026. TNG456 received FDA Orphan Drug Designation for malignant glioma. TNG260 showed a subgroup mPFS of 27 weeks in STK11mut/KRAS WT lung cancer. Financially, the company reported Q3 net income $15.9M and held $152.8M cash as of Sept 30, 2025, plus ~$212M net proceeds from an October 2025 financing that extends runway into 2028.
Tango Therapeutics (NASDAQ: TNGX) will report third quarter 2025 financial results on Tuesday, November 4, 2025 at 9:00 AM ET, to be released before the U.S. market open.
The company said it does not intend to hold a conference call with investors or analysts following the release.
Tango Therapeutics (Nasdaq: TNGX) priced an underwritten offering and a concurrent PIPE to raise approximately $225 million in gross proceeds. The offering includes 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares at a per-share price of $8.66 (pre-funded warrant price $8.659). Gross proceeds from the offering are expected to be about $210 million; the PIPE is selling 1,732,101 shares for about $15 million. The transactions are expected to close on or about October 24, 2025, subject to customary conditions.
Tango Therapeutics (NASDAQ: TNGX) reported positive Phase 1/2 data for vopimetostat (TNG462) in MTAP-deleted cancers dated October 23, 2025. Across 94 evaluable patients, the overall ORR is 27%, disease control rate 78%, and median PFS 6.4 months. In 2L MTAP-del pancreatic cancer (n=39 at active doses) ORR 25% and mPFS 7.2 months; company plans a ~300-patient global randomized pivotal trial in 2026 at the FDA-aligned dose 250 mg QD. A histology-agnostic cohort (excluding pancreatic, lung, sarcoma) showed ORR 49% and mPFS 9.1 months. Safety at 250 mg QD was generally tolerable; most common TRAEs were nausea, anemia, fatigue, dysgeusia, thrombocytopenia.